GEN Exclusives

More »

GEN News Highlights

More »
Sep 7, 2011

Orphazyme Closes €14M Financing to Advance Work in Lysosomal Storage Diseases

  • Orphazyme closed a €14 million ($19.6 million) series A financing round. Proceeds will go toward advancing the company’s lead program, Orph-001, into clinical development. Aescap Venture joined existing investors Novo and Sunstone Capital in the round.

    Orphazyme develops treatments for lysosomal storage diseases and has two projects in preclinical development. Orph-001 is a recombinant version of human HSP70. It is currently being tested in vivo in animal models in collaboration with academic laboratories.

    Orphazyme is based on discoveries of its scientific founders, Marja Jäättela, M.D., and Thomas Kirkegaard Jensen, Ph.D., a postdoc at the Danish Cancer Society (Kræftens Bekæmpelse). Novo provided grant funding before becoming a shareholder and was a founding investor in Orphazyme.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?